Breadcrumb Navigation

Melanom: A phase II, open label, single arm, single center study to evaluate pyrexia management (with or without any other cytokine release symptoms) using tocilizumab, an humanized monoclonal antibody against the Interleukin – 6 Receptor in melanoma patients treated with  BRAF/MEK inhibitors and/or immunotherapy

Stadium/Indikation inkl. Kurzinfo

Melanom – in Behandlung mit BRAF/MEK-Inhibitoren +/- Immuntherapie

Melanom-Patienten derzeit in Behandlung mit BRAF/MEK-Inhibitoren +/- Immun-therapie

anti-IL6 Therapie

Kurztitel

IIT Pyrexia-Management
NCT04652258

Offizieller Titel

A phase II, open label, single arm, single center study to evaluate pyrexia management (with or without any other cytokine release symptoms) using tocilizumab, an humanized monoclonal antibody against the Interleukin – 6 Receptor in melanoma patients treated with  BRAF/MEK inhibitors and/or immunotherapy

PI (Principal Investigator)

Prof. Reinhard Dummer

Zuständige Ärztin

Joëlle Dornbierer

Zuständige Ärztin

Ramon Stäger

Tel. +41 43 253 91 41

Behandelnder Fachbereich

Dermatologische Klinik